The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression

Open-label, single-group Phase II trial administering a single 25 mg oral dose of psilocybin with supportive psychotherapy to adults with bipolar II depression; primary objective is change in depressive symptoms.

Actual enrollment listed as 15. Outcomes include efficacy on depressive symptoms; safety and tolerability monitored under supportive conditions.